A5022516246- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Cancer, Hypoxia, and Metabolism
- Cancer Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Angiogenesis and VEGF in Cancer
- Cancer Genomics and Diagnostics
First Affiliated Hospital of Nanchang University
2022-2023
Nanchang University
2022-2023
Jiangxi Provincial Cancer Hospital
2023
Background Despite the fact that numerous clinical and preclinical studies have demonstrated synergistic effects of combining antiangiogenic or chemotherapy with immunotherapy, no data been found to indicate combination therapy is more effective safer as second-line therapy. Methods We retrospectively compared effectiveness safety ICIs plus rh-endostatin in patients advanced non-small cell lung cancer (NSCLC). The evaluation indicators this study were progression-free survival (PFS),...
Aim: To assess the efficacy and safety of combination PD-1 inhibitors, recombinant human endostatin (Rh-endostatin) chemotherapy as first-line treatment for advanced non-small-cell lung cancer (NSCLC). Methods: A total 100 patients with NSCLC were retrospectively reviewed analyzed (58 in group receiving inhibitors plus Rh-endostatin chemotherapy; 42 chemotherapy). The primary end point was progression-free survival. Results: Patients had significantly improved survival (10.2 vs 6.5 months; p...